# OnCo record keynote-062 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-062/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-062", "NCT02494583" ;
  schema:name "KEYNOTE-062"@en ;
  schema:description "KEYNOTE-062 found that pembrolizumab on its own was no worse than chemotherapy for survival in PD-L1-positive stomach cancer, but adding it to chemotherapy did not clearly beat chemotherapy alone; the tumours with the most PD-L1, and those with mismatch-repair deficiency, gained the most."@en ;
  schema:url <https://onco.cc/trials/keynote-062/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02494583> ;
  onco:status "mixed" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/gastric-pdl1-high/>, <https://onco.cc/cancers/gastric-msi-high/>, <https://onco.cc/cancers/gastric/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/shitara-kohei/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-062-shitara-jama-oncol-2020/> .